Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS)

Ulrich Ronellenfitsch, Antonia Dimitrakopoulou-Strauss, Jens Jakob, Bernd Kasper, Kai Nowak, Lothar R Pilz, Ulrike Attenberger, Timo Gaiser, Gerlinde Egerer, Stefan Fröhling, Hans-Günter Derigs, Matthias Schwarzbach, Peter Hohenberger, Ulrich Ronellenfitsch, Antonia Dimitrakopoulou-Strauss, Jens Jakob, Bernd Kasper, Kai Nowak, Lothar R Pilz, Ulrike Attenberger, Timo Gaiser, Gerlinde Egerer, Stefan Fröhling, Hans-Günter Derigs, Matthias Schwarzbach, Peter Hohenberger

Abstract

Introduction: For resectable soft tissue sarcoma (STS), radical surgery, usually combined with radiotherapy, is the mainstay of treatment and the only potentially curative modality. Since surgery is often complicated by large tumour size and extensive tumour vasculature, preoperative treatment strategies with the aim of devitalising the tumour are being explored. One option is treatment with antiangiogenic drugs. The multikinase inhibitor pazopanib, which possesses pronounced antiangiogenic effects, has shown activity in metastatic and unresectable STS, but has so far not been tested in the preoperative setting.

Methods and analysis: This open-label, multicentre phase II window-of-opportunity trial assesses pazopanib as preoperative treatment of resectable STS. Participants receive a 21-day course of pazopanib 800 mg daily during wait time for surgery. Major eligibility criteria are resectable, high-risk adult STS of any location, or metachronous solitary STS metastasis for which resection is planned, and adequate organ function and performance status. The trial uses an exact single-stage design. The primary end point is metabolic response rate (MRR), that is, the proportion of patients with >50% reduction of the mean standardised uptake value (SUVmean) in post-treatment compared to pre-treatment fluorodeoxyglucose positron emission tomography CT. The MRR below which the treatment is considered ineffective is 0.2. The MRR above which the treatment warrants further exploration is 0.4. With a type I error of 5% and a power of 80%, the sample size is 35 evaluable patients, with 12 or more responders as threshold. Main secondary end points are histopathological and MRI response, resectability, toxicity, recurrence-free and overall survival. In a translational substudy, endothelial progenitor cells and vascular epithelial growth factor receptor are analysed as potential prognostic and predictive markers.

Ethics and dissemination: Approval by the ethics committee II, University of Heidelberg, Germany (2012-019F-MA), German Federal Institute for Drugs and Medical Devices (61-3910-4038155) and German Federal Institute for Radiation Protection (Z5-22463/2-2012-007).

Trial registration number: NCT01543802, EudraCT: 2011-003745-18; Pre-results.

Keywords: Clinical trials

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Figures

Figure 1
Figure 1
Study flow chart (d, day; PET, positron emission tomography).

References

    1. ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25(Suppl 3):iii102–12. 10.1093/annonc/mdu254
    1. Hohenberger P, Wysocki WM. Neoadjuvant treatment of locally advanced soft tissue sarcoma of the limbs: which treatment to choose? Oncologist 2008;13:175–86. 10.1634/theoncologist.2007-0165
    1. Gortzak E, Azzarelli A, Buesa J et al. . A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma. Eur J Cancer 2001;37:1096–103. 10.1016/S0959-8049(01)00083-1
    1. Issels RD, Lindner LH, Verweij J et al. . Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 2010;11:561–70. 10.1016/S1470-2045(10)70071-1
    1. O'Sullivan B, Davis AM, Turcotte R et al. . Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 2002;359:2235–41. 10.1016/S0140-6736(02)09292-9
    1. Casali PG, Blay JY. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v198–203. 10.1093/annonc/mdq209
    1. Grimer R, Judson I, Peake D et al. . Guidelines for the management of soft tissue sarcomas. Sarcoma 2010;2010:506182 10.1155/2010/506182
    1. van der Graaf WT, Blay JY, Chawla SP et al. , EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879–86. 10.1016/S0140-6736(12)60651-5
    1. Sleijfer S, Ray-Coquard I, Papai Z et al. . Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009;27:3126–32. 10.1200/JCO.2008.21.3223
    1. Gotink KJ, Verheul HM. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis 2010;13:1–14. 10.1007/s10456-009-9160-6
    1. Hamberg P, Verweij J, Sleijfer S. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist 2010;15:539–47. 10.1634/theoncologist.2009-0274
    1. Glimelius B, Lahn M. Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology. Ann Oncol 2011;22:1717–25. 10.1093/annonc/mdq622
    1. Smith MA, Anderson B. Phase II window studies: 10 years of experience and counting. J Pediatr Hematol Oncol 2001;23:334–7. 10.1097/00043426-200108000-00002
    1. Altorki N, Lane ME, Bauer T et al. . Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J Clin Oncol 2010;28:3131–7. 10.1200/JCO.2009.23.9749
    1. Schuetze SM, Rubin BP, Vernon C et al. . Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 2005;103:339–48. 10.1002/cncr.20769
    1. Dimitrakopoulou-Strauss A, Strauss LG, Egerer G et al. . Impact of dynamic 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study. J Nucl Med 2010;51:551–8. 10.2967/jnumed.109.070862
    1. Dimitrakopoulou-Strauss A, Strauss LG, Egerer G et al. . Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis. Eur J Nucl Med Mol Imaging 2010;37:1481–9. 10.1007/s00259-010-1435-z
    1. Kasper B, Dietrich S, Dimitrakopoulou-Strauss A et al. . Early prediction of therapy outcome in patients with high-risk soft tissue sarcoma using positron emission tomography. Onkologie 2008;31:107–12. 10.1159/000113795
    1. Stacchiotti S, Collini P, Messina A et al. . High-grade soft-tissue sarcomas: tumor response assessment—pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology 2009;251:447–56. 10.1148/radiol.2512081403
    1. Dudeck O, Zeile M, Pink D et al. . Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas. J Magn Reson Imaging 2008;27:1109–13. 10.1002/jmri.21358
    1. Yoon SS, Segal NH, Olshen AB et al. . Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma. Ann Oncol 2004;15:1261–6. 10.1093/annonc/mdh309
    1. Investigator's Brochure for pazopanib (GW786034) for Oncology and Ophthalmic Indications. Version 09 2012.
    1. Sharma K, Marcus JR. Bevacizumab and wound-healing complications: mechanisms of action, clinical evidence, and management recommendations for the plastic surgeon. Ann Plast Surg 2013;71:434–40. 10.1097/SAP.0b013e31824e5e57
    1. Eisenhauer EA, Therasse P, Bogaerts J et al. . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47. 10.1016/j.ejca.2008.10.026
    1. Coindre JM. Grading of soft tissue sarcomas: review and update. Arch Pathol Lab Med 2006;130:1448–53.
    1. A'Hern RP. Sample size tables for exact single-stage phase II designs. Stat Med 2001;20:859–66. 10.1002/sim.721
    1. Benz MR, Allen-Auerbach MS, Eilber FC et al. . Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas. J Nucl Med 2008;49:1579–84. 10.2967/jnumed.108.053694
    1. Benz MR, Czernin J, Allen-Auerbach MS et al. . FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res 2009;15:2856–63. 10.1158/1078-0432.CCR-08-2537
    1. Evilevitch V, Weber WA, Tap WD et al. . Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res 2008;14:715–20. 10.1158/1078-0432.CCR-07-1762
    1. Roodhart JM, Langenberg MH, Daenen LG et al. . Translating preclinical findings of (endothelial) progenitor cell mobilization into the clinic; from bedside to bench and back. Biochim Biophys Acta 2009;1796:41–9. 10.1016/j.bbcan.2009.04.006
    1. Bolontrade MF, Zhou RR, Kleinerman ES. Vasculogenesis plays a role in the growth of Ewing's sarcoma in vivo. Clin Cancer Res 2002;8:3622–7.
    1. Davidoff AM, Ng CY, Brown P et al. . Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Clin Cancer Res 2001;7:2870–9.
    1. Norden-Zfoni A, Desai J, Manola J et al. . Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 2007;13:2643–50. 10.1158/1078-0432.CCR-06-0919
    1. Nowak K, Rafat N, Belle S et al. . Circulating endothelial progenitor cells are increased in human lung cancer and correlate with stage of disease. Eur J Cardiothorac Surg 2010;37:758–63. 10.1016/j.ejcts.2009.10.002
    1. Haas RL, Gelderblom H, Sleijfer S et al. . A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities. Acta Oncol 2015;54:1195–201. 10.3109/0284186X.2015.1037404
    1. Schuetze SM, Baker LH, Benjamin RS et al. . Selection of response criteria for clinical trials of sarcoma treatment. Oncologist 2008;13(Suppl 2):32–40. 10.1634/theoncologist.13-S2-32
    1. Griffioen AW, Mans LA, de Graaf AM et al. . Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin Cancer Res 2012;18:3961–71. 10.1158/1078-0432.CCR-12-0002
    1. Chaft JE, Oxnard GR, Sima CS et al. . Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 2011;17:6298–303. 10.1158/1078-0432.CCR-11-1468
    1. Mancuso MR, Davis R, Norberg SM et al. . Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006;116:2610–21. 10.1172/JCI24612
    1. Rini BI, Plimack ER, Takagi T et al. . A phase II study of pazopanib in patients with localized renal cell carcinoma to optimize preservation of renal parenchyma. J Urol 2015;194:297–303. 10.1016/j.juro.2015.03.096

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj